Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308366415> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4308366415 endingPage "66" @default.
- W4308366415 startingPage "62" @default.
- W4308366415 abstract "Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer does respond to chemotherapy but can be addressed with a better therapeutic index by using biologically modified endocrine therapy. The most pronounced recent successes were reached by antibody drug conjugates (ADCs).In early HR+/HER2- disease, adjuvant treatment escalations have taken place for high-risk patients using abemaciclib for the HR+ BRCA- subset and olaparib for HR+ BRCA+ patients. In metastatic spread, among all CDK (cyclin-dependent kinase) 4/6 inhibitors used for first-line therapy, only ribociclib improved overall survival in pre and postmenopausal patients. Palbociclib failed to demonstrate overall survival benefits. New options come up with oral selective oestrogen receptor degraders (SERDs) such as elacestrant, which will replace fulvestrant and is clinically important in combination therapies. ADCs, together with new patient categories such as HER2low or HER3+, enlarge the treatment portfolio and challenge the need of supportive care. The antitrophoblast antigen 2 (TROP2) ADC sacituzumab govitecan improves overall survival in heavily pretreated HR+/HER2- patients by 3.2 months. The best improvement of overall survival was shown bý trastuzumab deruxtecan in less pretreated HER2low (HER2 1+ or HER2 2+/no gene amplification) patients with a gained life span of 6 months.Real-world data on the sequence of different ADCs with similar payloads are needed to establish best possible treatment algorithms. All these new agents will find their place after CDK4/6 inhibitor-based endocrine combination therapy." @default.
- W4308366415 created "2022-11-11" @default.
- W4308366415 creator A5035775338 @default.
- W4308366415 date "2022-11-07" @default.
- W4308366415 modified "2023-09-23" @default.
- W4308366415 title "New treatment options for hormone receptor positive breast cancer in 2023" @default.
- W4308366415 cites W2804105316 @default.
- W4308366415 cites W3013833162 @default.
- W4308366415 cites W3165576985 @default.
- W4308366415 cites W3167855488 @default.
- W4308366415 cites W3206169364 @default.
- W4308366415 cites W4221085715 @default.
- W4308366415 cites W4225380120 @default.
- W4308366415 cites W4226097966 @default.
- W4308366415 cites W4280490473 @default.
- W4308366415 cites W4281640394 @default.
- W4308366415 cites W4297613872 @default.
- W4308366415 doi "https://doi.org/10.1097/gco.0000000000000834" @default.
- W4308366415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36341983" @default.
- W4308366415 hasPublicationYear "2022" @default.
- W4308366415 type Work @default.
- W4308366415 citedByCount "0" @default.
- W4308366415 crossrefType "journal-article" @default.
- W4308366415 hasAuthorship W4308366415A5035775338 @default.
- W4308366415 hasConcept C121608353 @default.
- W4308366415 hasConcept C126322002 @default.
- W4308366415 hasConcept C143998085 @default.
- W4308366415 hasConcept C2775930923 @default.
- W4308366415 hasConcept C2777176818 @default.
- W4308366415 hasConcept C2778812593 @default.
- W4308366415 hasConcept C2779744173 @default.
- W4308366415 hasConcept C2779786085 @default.
- W4308366415 hasConcept C2780482068 @default.
- W4308366415 hasConcept C530470458 @default.
- W4308366415 hasConcept C71924100 @default.
- W4308366415 hasConcept C84606932 @default.
- W4308366415 hasConceptScore W4308366415C121608353 @default.
- W4308366415 hasConceptScore W4308366415C126322002 @default.
- W4308366415 hasConceptScore W4308366415C143998085 @default.
- W4308366415 hasConceptScore W4308366415C2775930923 @default.
- W4308366415 hasConceptScore W4308366415C2777176818 @default.
- W4308366415 hasConceptScore W4308366415C2778812593 @default.
- W4308366415 hasConceptScore W4308366415C2779744173 @default.
- W4308366415 hasConceptScore W4308366415C2779786085 @default.
- W4308366415 hasConceptScore W4308366415C2780482068 @default.
- W4308366415 hasConceptScore W4308366415C530470458 @default.
- W4308366415 hasConceptScore W4308366415C71924100 @default.
- W4308366415 hasConceptScore W4308366415C84606932 @default.
- W4308366415 hasIssue "1" @default.
- W4308366415 hasLocation W43083664151 @default.
- W4308366415 hasLocation W43083664152 @default.
- W4308366415 hasOpenAccess W4308366415 @default.
- W4308366415 hasPrimaryLocation W43083664151 @default.
- W4308366415 hasRelatedWork W2740803632 @default.
- W4308366415 hasRelatedWork W2751810360 @default.
- W4308366415 hasRelatedWork W2892008472 @default.
- W4308366415 hasRelatedWork W2931385471 @default.
- W4308366415 hasRelatedWork W2943438364 @default.
- W4308366415 hasRelatedWork W3203106735 @default.
- W4308366415 hasRelatedWork W3203690439 @default.
- W4308366415 hasRelatedWork W4220718209 @default.
- W4308366415 hasRelatedWork W4226356606 @default.
- W4308366415 hasRelatedWork W4282924254 @default.
- W4308366415 hasVolume "35" @default.
- W4308366415 isParatext "false" @default.
- W4308366415 isRetracted "false" @default.
- W4308366415 workType "article" @default.